A Phase I/II, Open-Label Study of JX-594 (Thymidine Kinase-Deleted Vaccinia Virus Plus GM-CSF) Administered by Intratumoral Injection in Patients With Unresectable Stage 3 or Stage 4 Malignant Melanoma

Trial Profile

A Phase I/II, Open-Label Study of JX-594 (Thymidine Kinase-Deleted Vaccinia Virus Plus GM-CSF) Administered by Intratumoral Injection in Patients With Unresectable Stage 3 or Stage 4 Malignant Melanoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 19 Jan 2015

At a glance

  • Drugs Pexastimogene devacirepvec (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors Jennerex
  • Most Recent Events

    • 06 Apr 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
    • 06 Apr 2010 Status changed from suspended to completed as reported by ClinicalTrials.gov.
    • 13 Oct 2009 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top